Analyzing ABIVAX Société Anonyme (NASDAQ:ABVX) and Astellas Pharma (OTCMKTS:ALPMY)

ABIVAX Société Anonyme (NASDAQ:ABVX) and Astellas Pharma (OTCMKTS:ALPMY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Insider & Institutional Ownership

47.9% of ABIVAX Société Anonyme shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ABIVAX Société Anonyme and Astellas Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ABIVAX Société Anonyme	N/A	N/A	N/A
Astellas Pharma	3.26%	10.33%	4.62%

Valuation & Earnings

This table compares ABIVAX Société Anonyme and Astellas Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABIVAX Société Anonyme	N/A	N/A	-$159.90 million	N/A	N/A
Astellas Pharma	$11.11 billion	1.82	$113.00 million	$0.21	53.19

Astellas Pharma has higher revenue and earnings than ABIVAX Société Anonyme.

Analyst Ratings

This is a summary of current ratings for ABIVAX Société Anonyme and Astellas Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABIVAX Société Anonyme	0	1	6	0	2.86
Astellas Pharma	0	0	0	0	0.00

ABIVAX Société Anonyme currently has a consensus price target of $36.50, indicating a potential upside of 248.62%. Given ABIVAX Société Anonyme’s stronger consensus rating and higher possible upside, equities analysts plainly believe ABIVAX Société Anonyme is more favorable than Astellas Pharma.

Summary

Astellas Pharma beats ABIVAX Société Anonyme on 5 of the 9 factors compared between the two stocks.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

About Astellas Pharma

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.